ATE297981T1 - Herstellung von vakzinen unter der verwendung von hybrid-zellen - Google Patents

Herstellung von vakzinen unter der verwendung von hybrid-zellen

Info

Publication number
ATE297981T1
ATE297981T1 AT01908591T AT01908591T ATE297981T1 AT E297981 T1 ATE297981 T1 AT E297981T1 AT 01908591 T AT01908591 T AT 01908591T AT 01908591 T AT01908591 T AT 01908591T AT E297981 T1 ATE297981 T1 AT E297981T1
Authority
AT
Austria
Prior art keywords
cells
hybrid cells
hybrid
vaccines
production
Prior art date
Application number
AT01908591T
Other languages
English (en)
Inventor
Thomas Wagner
Yanzhang Wei
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Application granted granted Critical
Publication of ATE297981T1 publication Critical patent/ATE297981T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01908591T 2000-01-11 2001-01-09 Herstellung von vakzinen unter der verwendung von hybrid-zellen ATE297981T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17537600P 2000-01-11 2000-01-11
PCT/US2001/000571 WO2001051608A2 (en) 2000-01-11 2001-01-09 Hybrid cells obtainable from antigen presenting cells

Publications (1)

Publication Number Publication Date
ATE297981T1 true ATE297981T1 (de) 2005-07-15

Family

ID=22640013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908591T ATE297981T1 (de) 2000-01-11 2001-01-09 Herstellung von vakzinen unter der verwendung von hybrid-zellen

Country Status (11)

Country Link
US (2) US6849451B2 (de)
EP (1) EP1248836B1 (de)
JP (1) JP2003519486A (de)
CN (1) CN1427889B (de)
AT (1) ATE297981T1 (de)
AU (1) AU783931B2 (de)
CA (2) CA2823768A1 (de)
DE (1) DE60111490T2 (de)
DK (1) DK1248836T3 (de)
ES (1) ES2240417T3 (de)
WO (1) WO2001051608A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058017A1 (en) * 1999-01-15 2004-03-25 Chow Sek Chuen Pro-apoptotic agents
US20050009740A1 (en) * 2003-03-31 2005-01-13 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
JP2007528375A (ja) * 2004-03-02 2007-10-11 典也 大野 癌の治療および予防用雑種細胞ワクチンの方法および組成物
WO2007130050A1 (en) * 2006-05-08 2007-11-15 Wagner Thomas E Hybrid cells for treating early and late stage-ned melanoma
AU2008323853B8 (en) * 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
EP2569416A4 (de) * 2010-05-10 2013-11-13 Orbis Health Solutions Llc Verfahren zur erstellung und sortierung fusionierter zellen
CN105821030A (zh) * 2015-01-04 2016-08-03 彭霞 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859584A (en) 1986-10-31 1989-08-22 Smithkline Beckman Corporation Cell growth rate determination by measurement of changes in cyanine dye levels in plasma membranes
US4762701A (en) 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4783401A (en) 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
JP2907473B2 (ja) 1988-09-27 1999-06-21 カイロン コーポレーション 細胞選別技術及びその利用
WO1996030030A1 (en) 1995-03-31 1996-10-03 Universite Libre De Bruxelles Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
EP1007720B1 (de) * 1997-04-15 2008-03-05 Dana Farber Cancer Institute, Inc. Dendritische zellhybride
US6197593B1 (en) * 1998-10-20 2001-03-06 Coulter International Corp. Method for enumerating blood cells

Also Published As

Publication number Publication date
US6849451B2 (en) 2005-02-01
CA2396992C (en) 2013-10-29
CN1427889B (zh) 2011-06-29
CA2396992A1 (en) 2001-07-19
CN1427889A (zh) 2003-07-02
DE60111490D1 (de) 2005-07-21
WO2001051608A2 (en) 2001-07-19
ES2240417T3 (es) 2005-10-16
US20010049142A1 (en) 2001-12-06
CA2823768A1 (en) 2001-07-19
EP1248836B1 (de) 2005-06-15
WO2001051608A3 (en) 2001-12-27
US20050158244A1 (en) 2005-07-21
HK1057233A1 (en) 2004-03-19
AU3644301A (en) 2001-07-24
JP2003519486A (ja) 2003-06-24
EP1248836A2 (de) 2002-10-16
DE60111490T2 (de) 2006-05-18
AU783931B2 (en) 2005-12-22
DK1248836T3 (da) 2005-08-15

Similar Documents

Publication Publication Date Title
AU641488B2 (en) Human hematopoietic stem cell
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
ATE139574T1 (de) Herstellung von proteinen mittels homologer rekombination
DE69633669D1 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
DE69426692D1 (de) Methode zur herstellung von taxan-diterpen und methode zum einten von kulturzellen, die taxan-diterpen in hohen ausbeuten herstellen
DE69518437D1 (de) Verfahren zur herstellung transformierter zellen
DE3888642D1 (de) Rollflasche zur Züchtung von Zellengewebekulturen.
ATE153214T1 (de) Medien zur zellzucht und verfahren dazu
JPS6447381A (en) Preparation of liposome containing sealed gene
WO1992020796A3 (en) D-type cyclin and uses related thereto
ATE297981T1 (de) Herstellung von vakzinen unter der verwendung von hybrid-zellen
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
DE60044871D1 (de) Sphäroidische vorbereitung
WO2004033627A3 (en) Methods for efficient production of mammalian recombinant proteins
MXPA02006094A (es) Metodos para producir embriones clonadod y adultos a partir de celulas cultivadas.
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
ATE366803T1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
WO2005054447A3 (en) Müller stem cells
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
DE3071618D1 (en) Thermophilic aspartase, processes for producing, culture used, and l-aspartic acid preparation process using the same
WO2004078915A3 (en) Cell culture
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
EP1541675A3 (de) Aus Antigene presentierenden Zellen erhärtlich Zellhybride

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1248836

Country of ref document: EP